問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


China Medical University Hospital (在職)

Division of General Surgery

Division of Hematology & Oncology

Chung Shan Medical University Hospital (在職)

Division of Hematology & Oncology

更新時間：2023-09-19

蔡明宏Tsai, Ming-Hung
  • Co-Principal Investigator
  • Clinical Trial Experience (year) 12 years 9 個月

Recruiting Trial

68Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

蔡明宏

List

109Cases

2021-12-01 - 2029-05-10

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting2Sites

Terminated1Sites

2017-11-01 - 2020-03-19

Phase II/III

A Phase II/III, Randomised, Multicentre Study of MOR00208 with Bendamustine versus Rituximab with Bendamustine in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) Who Are Not Eligible for High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT) ─ B-MIND

  • Condition/Disease

    Diffuse Large B-cell Lymphoma

  • Test Drug

    MOR00208

Participate Sites
8Sites

Not yet recruiting6Sites

Recruiting1Sites

白禮源
China Medical University Hospital-Taipei

未分科

2018-08-18 - 2022-07-11

Phase III

FIGHT: A Phase 3 Randomized, Double-Blind, Controlled Study Evaluating FPA144 and Modified FOLFOX6 in Patients with Previously Untreated Advanced Gastric and Gastroesophageal Cancer: Phase 3 Preceded by Dose-Finding in Phase 1

  • Condition/Disease

    Untreated Advanced Gastric and Gastroesophageal Cancer

  • Test Drug

    FPA144

Participate Sites
9Sites

Not yet recruiting3Sites

Recruiting1Sites

Terminated4Sites

白禮源
China Medical University Hospital-Taipei

未分科

2019-04-01 - 2025-06-30

Phase II

A Phase 2, Open-Label, Randomized Study to Assess the Antitumor Activity and Safety of Zolbetuximab (IMAB362) in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma

  • Condition/Disease

    Pancreatic Adenocarcinoma

  • Test Drug

    Zolbetuximab (IMAB362)

Participate Sites
8Sites

Recruiting8Sites

2020-09-20 - 2024-02-22

Phase I

A Phase I, Open-Label Study to Assess the Safety, Tolerability, and Preliminary Efficacy of OBI-866/OBI-821, a Novel Anti-Stage-Specific Embryonic Antigen-4 (SSEA-4) Active Immunotherapy, in Patients with Advanced/Metastatic Cancers of the Ovary, Kidney, Brain, Pancreas, Breast or Lung

  • Condition/Disease

    Cancers of the Ovary, Kidney, Brain, Pancreas, Breast or Lung

  • Test Drug

    OBI-866 (SSEA-4) / OBI-821 (adjuvant)

Participate Sites
2Sites

Recruiting2Sites

白禮源
China Medical University Hospital

Division of Hematology & Oncology

2015-06-30 - 2017-12-31

Phase IV

A post marketing surveillance study of Lipo-AB® (amphotericin B) in neutropenic patients with persistent fever

  • Condition/Disease

    neutropenic

  • Test Drug

    amphotericin B

Participate Sites
10Sites

Terminated9Sites

李文生
Taipei WanFang Hospital (Managed by Taipei Medical Univeristy)

Division of Infectious Disease

2017-05-09 - 2018-04-22

Phase I/II

A Phase 1/2, Open-label Randomized Study of Ulocuplumab (BMS-936564) in Combination With Low Dose Cytarabine in Subjects With Newly Diagnosed Acute Myeloid Leukemia

  • Condition/Disease

    Acute Myeloid Leukemia (AML)

  • Test Drug

    Ulocuplumab (BMS-936564)

Participate Sites
6Sites

Terminated5Sites

2017-08-01 - 2022-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated7Sites

2019-03-01 - 2021-12-31

Phase I

A Phase I Dose Escalation Study, With Cohort Expansion, to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AbGn-107 Therapy in Patients With Chemo-refractory Locally Advanced, Recurrent, or Metastatic Gastric, Colorectal, Pancreatic or Biliary Cancer

  • Condition/Disease

    Gastric, Colorectal, Pancreatic or Biliary Cancer

  • Test Drug

    AbGn-107

Participate Sites
3Sites

Terminated3Sites

1 7 8 9 10 11
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB